Fisetin, a natural flavonoid found in fruits and vegetables like strawberries and apples, has shown significant potential in combating metabolic dysfunction-associated fatty liver disease (MAFLD). MAFLD, a chronic liver condition linked to obesity, insulin resistance, and type 2 diabetes, affects nearly 30% of the global population.
Fisetin, a natural flavonoid found in fruits and vegetables like strawberries and apples, has shown significant potential in combating metabolic dysfunction-associated fatty liver disease (MAFLD). MAFLD, a chronic liver condition linked to obesity, insulin resistance, and type 2 diabetes, affects nearly 30% of the global population. In a study using a high-fat diet (HFD)-induced mouse model and sodium oleate (OA)-treated HepG2 cells, fisetin demonstrated remarkable therapeutic effects against MAFLD progression.
Fisetin significantly reduced body weight gain, liver mass, and fat accumulation in HFD-fed mice without altering food intake, indicating metabolic improvement. It improved blood glucose levels, glucose tolerance, and lipid profiles, including lowering triglycerides, total cholesterol, and LDL-C while increasing protective HDL-C levels. Fisetin also enhanced liver function by reducing serum AST and ALT levels, markers of hepatic injury.
Histological analyses confirmed reduced hepatic lipid accumulation and increased glycogen storage, reflecting improved glucose utilization and suppressed gluconeogenesis. Fisetin restored antioxidant balance by enhancing superoxide dismutase (SOD) activity and reducing reactive oxygen species (ROS) and nitric oxide (NO) levels. Mechanistically, fisetin activated the GSK-3β/Nrf2/HO-1 pathway, upregulated antioxidant enzymes, and downregulated gluconeogenic enzymes (PEPCK, G6PC), promoting glucose and lipid homeostasis. These findings suggest fisetin as a promising natural therapeutic for MAFLD.
Introduction: Chronic hepatitis B (CHB), hepatic steatosis, and type 2 diabetes mellitus (T2DM) frequently coexist, creating a growing clinical challenge. This multinational study evaluated whether T2DM independently influences liver histology in treatment-naïve CHB patients with...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes, and cardiovascular disease. While both tirzepatide and SGLT2 inhibitors improve metabolic health, comparative real-world data on long-term liver and cardiovascular outcomes have...
Introduction: GLP-1 receptor agonists (GLP-1RAs) have revolutionized obesity treatment, producing substantial weight loss and cardiometabolic benefits. However, many patients discontinue therapy because of cost, adverse effects, or limited access, and weight regain frequently follows. This...
Introduction: The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is evolving rapidly with the emergence of incretin-based therapies. Beyond improving weight and glycemic control, these agents are showing promise in resolving steatohepatitis and slowing fibrosis...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.